{
    "clinical_study": {
        "@rank": "41786", 
        "acronym": "DRAGON", 
        "arm_group": [
            {
                "arm_group_label": "Ranibizumab 0.5 mg monthly", 
                "arm_group_type": "Experimental", 
                "description": "Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period"
            }, 
            {
                "arm_group_label": "Ranibizumab 0.5 mg PRN", 
                "arm_group_type": "Experimental", 
                "description": "PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 23 month treatment period"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the efficacy and safety of two different dosing regimens of\n      ranibizumab (either monthly injections or injections as-needed based on the stability of a\n      patient's vision) in Chinese patients with wet AMD . This study is to provide long-term\n      safety data in the treatment of Chinese patients with wet AMD."
        }, 
        "brief_title": "Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neovascular Age-related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with visual impairment due to neovascular AMD\n\n          -  A qualifying vision score at study entry Exclusion criteria\n\n          -  Active infection or inflammation either eye at study entry\n\n          -  Uncontrolled glaucoma in either eye\n\n          -  Any disorder in the study eye which may affect vision\n\n          -  Use of any systemic anti-VEGF-drugs within 3 months prior to study entry\n\n          -  Previous treatment of the study eye for wet AMD\n\n          -  Any surgery in the study eye 3 months prior to or planned with 6 month after study\n             entry Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775124", 
            "org_study_id": "CRFB002A2413"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ranibizumab 0.5 mg monthly", 
                "Ranibizumab 0.5 mg PRN"
            ], 
            "description": "Intravitreal injections of 0.5 mg Ranibizumab", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100730"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100083"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400042"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lanzhou", 
                        "country": "China", 
                        "state": "Gansu", 
                        "zip": "730030"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510060"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang", 
                        "zip": "150086"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430060"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha City", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410011"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanchang", 
                        "country": "China", 
                        "state": "Jiangxi", 
                        "zip": "330006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "2666000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taiyuan", 
                        "country": "China", 
                        "state": "Shanxi", 
                        "zip": "030002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shanxi", 
                        "zip": "710032"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "325027"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100044"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100730"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100176"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400038"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200092"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200031"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular AMD", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the VA averaged across all visits from Month 4 through 12 and the Month 3 Level of Visual Acuity (Letters) of the Study Eye. The treatment regimen up to Month 3 is the same in both treatment groups.", 
            "measure": "Average change in Visual Acuity (Letters) from Month 3 through Month 12", 
            "safety_issue": "No", 
            "time_frame": "Month 3 through Month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775124"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline", 
                "measure": "Change from Baseline in Visual Acuity (Letters) of the Study Eye over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Month 24"
            }, 
            {
                "description": "Visual acuity (VA) was at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient improved by equal or more than 5, 10, 15,or 30 letters of VA as compared to baseline.", 
                "measure": "Gain of equal or more than 5, 10, 15, or 30 letters in Visual Acuity of the Study Eye over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Month 24"
            }, 
            {
                "description": "Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.", 
                "measure": "Loss of less than 15 Letters of Visual Acuity in the study eye over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Month 24"
            }, 
            {
                "description": "Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for Month 12 and Month 24 whether a patient had a VA score of 73 or more letters", 
                "measure": "Visual Acuity of more of 73 letters or more", 
                "safety_issue": "No", 
                "time_frame": "Month 12 and 24"
            }, 
            {
                "description": "Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the average level of VA over all monthly post-baseline assessments from Month 4 to Month 24 and the Month 3 Level of VA. The treatment regimen up to Month 3 is the same in both treatment groups.", 
                "measure": "Average Visual Acuity change (Letters) from Month 3 to Month 4 through Month 24", 
                "safety_issue": "No", 
                "time_frame": "Month 3 to Month 24"
            }, 
            {
                "description": "Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between VA averaged across all visits from Month 1 through Month 12 (24) and the baseline VA level", 
                "measure": "Average Visual Acuity change (Letters) from baseline to Month 1 through Month 12 (24) ,", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Month 24"
            }, 
            {
                "description": "Central Sub-Field Thickness (CSFT) was assessed by Optical Coherence Tomography (OCT) and analyzed by a Central Reading Center. This outcome measure describes the change in CSFT at each visit compared to baseline", 
                "measure": "Change from Baseline in Central Sub-Field Thickness (CSFT) of the study eye over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Month 24"
            }, 
            {
                "description": "Date and reason for treatment with ranibizumab will be collected on the dosage administration page. This outcome measure describes the number of re-treatments with ranibizumab in patients with (PRN)as needed dosing, duration of active treatment phases and duration of treatment-free intervals.", 
                "measure": "Number of re-treatments and re-treatment patterns over time in patients receiving PRN dosing of ranibizumab 0.5 mg", 
                "safety_issue": "No", 
                "time_frame": "Month 4 to Month 12 (24)"
            }, 
            {
                "description": "Ocular and non-ocular adverse events will be collected through non-directive questioning at every visit during the entire duration of the study.", 
                "measure": "Frequency and severity of ocular and non-ocular adverse events over time", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to Month 24"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}